白细胞介素-6与类风湿性关节炎  

Interleukin-6 and rheumatoid arthritis

作　　者：王书侠[1] 房国祥[1] 李晓军[1] 

机构地区：[1]南京军区南京总医院解放军临床检验医学研究所,南京210002

出　　处：《医学研究生学报》2009年第10期1098-1101,共4页Journal of Medical Postgraduates

基　　金：江苏省科教兴卫医学重点人才基金课题资助(批准号:RC2007.11.7)

摘　　要：类风湿性关节炎(RA)是以关节滑膜炎为特征的自身免疫性疾病(AID),细胞因子(CK)贯穿RA的整个病程。重要的CK如TNF-α、白细胞介素-1β(IL-1β)在促进关节滑膜细胞增生和炎症进程中起举足轻重的作用。近年来,临床对RA的治疗主要以这些CK为靶点,然而TNF-α、IL-1β阻断剂只对部分患者有效,逐渐增多的不良反应如继发感染、恶性肿瘤的发生等也逐渐引起关注。白细胞介素-6(IL-6)的异常表达和失调与RA的病情密切相关,是RA发病的重要调控因子,阻断剂可能用于RA的临床治疗。Rheumatoid arthritis（RA） is an autoimmune disease（AID） characterized by arthrosynovitis.Cytokines are involved in the whole course of the disease.Such important cytokines as TNF-α and IL-1β play a key role in the proliferation of synovial cells and progression of inflammation,and,therefore,have been taken as clinical therapeutic targets for RA in the recent years.The blocking agent of TNF-α or IL-1β is effective for only a few patients and the increasing adverse events it causes,such as infection and malignancy,are arousing more and more concern.The abnormal expression and imbalance of interleukin-6（IL-6） are closely associated with RA.IL-6 is an important regulatory factor for the pathogenesis of RA,and the blocking agent may be applied to the treatment of the disease.

关 键 词：白细胞介素-6 关节炎 类风湿性 

分 类 号：R593.22[医药卫生—内科学]